Anna Linko-Parvinen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anna Linko-Parvinen has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Hanna-Mari Pallari
Turku University Hospital
2 shared publications - Kari Eino Juhani Airaksinen
Turku University Hospital and University of Turku
2 shared publications - Saara Wittfooth
University of Turku
2 shared publications - Samuli Jaakkola
Turku University Hospital and University of Turku
2 shared publications - Selma Salonen
University of Turku
2 shared publications - Tuomas Paana
Turku University Hospital
2 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e044092
Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction
Background: Elevated troponin levels are a frequent finding in patients presenting with atrial fibrillation or atrial flutter (AF) to the emergency department but are seldom caused by myocardial infarction (MI). The current high‐sensitivity cTnT (cardiac troponin T) assay measures both the intact and highly fragmented cTnT forms (total cTnT) and detects cTnT elevations in conditions causing myocardial injury or MI without distinction between the 2. Methods: The SuperTROPO (Better Diagnostics of Myocardial Infarction With a Test for Special Forms of Troponin) study included 521 consecutive patients with AF only and 188 patients with MI only (139 Type 1 MI), all with a total cTnT value ≥14 ng/L at emergency department admission. Intact and long forms of cTnT (long cTnT) were analyzed from the first plasma samples using a novel immunoassay. The diagnostic performance of long cTnT and total cTnT assays was compared in these cases with elevated total cTnT. Results: Long cTnT was superior to total cTnT in discriminating troponin elevations in patients with MI from those in patients with AF (area under the curve for type 1 MI: 0.879 versus 0.783; for any MI: 0.864 versus 0.779; both P <0.001) when measured from the first blood sample without a significant effect of sex, age, estimated glomerular filtration rate, or total cTnT <200 ng/L. The difference in long cTnT levels was most notable in patients presenting within 12 hours of symptom onset. Conclusions: The long cTnT immunoassay shows that the troponin release in AF is composed mainly of smaller troponin fragments. This novel test holds promise that measuring long cTnT forms could help to separate troponin elevations caused by AF from those of acute Type 1 MI from a single sample with better accuracy than the commercial high‐sensitivity cTnT test. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05858112.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e044092
Open AccessLong Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction
Background: Elevated troponin levels are a frequent finding in patients presenting with atrial fibrillation or atrial flutter (AF) to the emergency department but are seldom caused by myocardial infarction (MI). The current high‐sensitivity cTnT (cardiac troponin T) assay measures both the intact and highly fragmented cTnT forms (total cTnT) and detects cTnT elevations in conditions causing myocardial injury or MI without distinction between the 2. Methods: The SuperTROPO (Better Diagnostics of Myocardial Infarction With a Test for Special Forms of Troponin) study included 521 consecutive patients with AF only and 188 patients with MI only (139 Type 1 MI), all with a total cTnT value ≥14 ng/L at emergency department admission. Intact and long forms of cTnT (long cTnT) were analyzed from the first plasma samples using a novel immunoassay. The diagnostic performance of long cTnT and total cTnT assays was compared in these cases with elevated total cTnT. Results: Long cTnT was superior to total cTnT in discriminating troponin elevations in patients with MI from those in patients with AF (area under the curve for type 1 MI: 0.879 versus 0.783; for any MI: 0.864 versus 0.779; both P <0.001) when measured from the first blood sample without a significant effect of sex, age, estimated glomerular filtration rate, or total cTnT <200 ng/L. The difference in long cTnT levels was most notable in patients presenting within 12 hours of symptom onset. Conclusions: The long cTnT immunoassay shows that the troponin release in AF is composed mainly of smaller troponin fragments. This novel test holds promise that measuring long cTnT forms could help to separate troponin elevations caused by AF from those of acute Type 1 MI from a single sample with better accuracy than the commercial high‐sensitivity cTnT test. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05858112.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 931-941
Evaluation of performance in preanalytical phase EQA: can laboratories mitigate common pitfalls?
Objectives: Preanalytical phase is an elemental part of laboratory diagnostics, but is prone to humane errors. The aim of this study was to evaluate performance in preanalytical phase external quality assessment (EQA) cases. We also suggest preventive actions for risk mitigation. Methods: We included 12 EQA rounds (Labquality Ltd.) with three patient cases (36 cases, 54–111 participants, 7–15 countries) published in 2018–2023. We graded performance according to percentage of correct responses in each case as ≥900 % excellent, 70–89 % good, 50–69 % satisfactory, 30–49 % fair and <30 % poor. Performance was simultaneously failed with ≥10 % of responses leading to harmful events. Results: Overall performance was excellent in 7, good in 12, satisfactory in 10, fair in 4 and poor in 3 cases. Additionally, 7 cases showed failed performance. Routine requests with incorrect sample tubes or incorrect sample handling were detected with good performance. Lower performance was seen with sudden abnormal results, with rare requests, with false patient identification (never-events) and with incorrect test requests. Information technology (IT) solutions (preanalytical checklists, autoverification rules and patient specific notifications) could have prevented 33 of 36 preanalytical errors. Conclusions: While most common errors were detected with good performance, samples with rare requests or those requiring individualised consideration are vulnerable to human misinterpretation. In many instances, samples with preanalytical errors should have been identified and rejected before reaching the laboratory or being directed to analysis. Optimising IT solutions to effectively detect these preanalytical errors allows for focus on infrequent events demanding accessible professional consultation. EQA preanalytical cases may help in education of correct actions in these occasions.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 931-941
Evaluation of performance in preanalytical phase EQA: can laboratories mitigate common pitfalls?
Objectives: Preanalytical phase is an elemental part of laboratory diagnostics, but is prone to humane errors. The aim of this study was to evaluate performance in preanalytical phase external quality assessment (EQA) cases. We also suggest preventive actions for risk mitigation. Methods: We included 12 EQA rounds (Labquality Ltd.) with three patient cases (36 cases, 54–111 participants, 7–15 countries) published in 2018–2023. We graded performance according to percentage of correct responses in each case as ≥900 % excellent, 70–89 % good, 50–69 % satisfactory, 30–49 % fair and <30 % poor. Performance was simultaneously failed with ≥10 % of responses leading to harmful events. Results: Overall performance was excellent in 7, good in 12, satisfactory in 10, fair in 4 and poor in 3 cases. Additionally, 7 cases showed failed performance. Routine requests with incorrect sample tubes or incorrect sample handling were detected with good performance. Lower performance was seen with sudden abnormal results, with rare requests, with false patient identification (never-events) and with incorrect test requests. Information technology (IT) solutions (preanalytical checklists, autoverification rules and patient specific notifications) could have prevented 33 of 36 preanalytical errors. Conclusions: While most common errors were detected with good performance, samples with rare requests or those requiring individualised consideration are vulnerable to human misinterpretation. In many instances, samples with preanalytical errors should have been identified and rejected before reaching the laboratory or being directed to analysis. Optimising IT solutions to effectively detect these preanalytical errors allows for focus on infrequent events demanding accessible professional consultation. EQA preanalytical cases may help in education of correct actions in these occasions.
- Open Access
- 17 November 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002954
Composition of cardiac troponin release differs after marathon running and myocardial infarction
Objectives: Elevations of cardiac troponin T (cTnT) levels are common after strenuous exercise. We assessed whether the composition of cTnT release after marathon race differs from that of acute myocardial infarction (MI). Methods: Troponin composition was analysed in plasma samples taken from 45 runners after marathon race and from 84 patients with type 1 MI. The concentration of long cTnT (intact and mildly fragmented cTnT) was measured with a novel upconversion luminescence immunoassay, total cTnT with a commercial high-sensitivity cTnT assay, and the ratio of long to total cTnT (troponin ratio) was determined as a measure of troponin fragmentation. Results: Total cTnT exceeded the upper reference limit (>14 ng/L) in 37 (82%) runners. Troponin ratio was lower in runners ((IQR) 0.17 (0.11–0.24) vs 0.62 (0.29–0.96), p<0.001). With increasing troponin release the troponin ratio decreased (r=−0.497, p<0.001) in marathon runners and the concentration of long cTnT remained in all runners below 8.4 ng/L. In contrast to marathon runners, troponin ratio increased (r=0.565, p<0.001) with the increase of cTnT release in patients with MI. The median total and long cTnT concentrations were lower in marathon runners than in patients with MI (25 ng/L vs 835 ng/L and 4.1 vs 385 ng/L, p<0.001 for both). Conclusion: In contrast to type 1 MI, only a small fraction of circulating cTnT exists as intact cTnT or long molecular forms after strenuous exercise and the difference in troponin composition is more pronounced in runners with higher troponin release. Trial registration number: NCT06000930.
- 17 November 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002954
Open AccessComposition of cardiac troponin release differs after marathon running and myocardial infarction
Objectives: Elevations of cardiac troponin T (cTnT) levels are common after strenuous exercise. We assessed whether the composition of cTnT release after marathon race differs from that of acute myocardial infarction (MI). Methods: Troponin composition was analysed in plasma samples taken from 45 runners after marathon race and from 84 patients with type 1 MI. The concentration of long cTnT (intact and mildly fragmented cTnT) was measured with a novel upconversion luminescence immunoassay, total cTnT with a commercial high-sensitivity cTnT assay, and the ratio of long to total cTnT (troponin ratio) was determined as a measure of troponin fragmentation. Results: Total cTnT exceeded the upper reference limit (>14 ng/L) in 37 (82%) runners. Troponin ratio was lower in runners ((IQR) 0.17 (0.11–0.24) vs 0.62 (0.29–0.96), p<0.001). With increasing troponin release the troponin ratio decreased (r=−0.497, p<0.001) in marathon runners and the concentration of long cTnT remained in all runners below 8.4 ng/L. In contrast to marathon runners, troponin ratio increased (r=0.565, p<0.001) with the increase of cTnT release in patients with MI. The median total and long cTnT concentrations were lower in marathon runners than in patients with MI (25 ng/L vs 835 ng/L and 4.1 vs 385 ng/L, p<0.001 for both). Conclusion: In contrast to type 1 MI, only a small fraction of circulating cTnT exists as intact cTnT or long molecular forms after strenuous exercise and the difference in troponin composition is more pronounced in runners with higher troponin release. Trial registration number: NCT06000930.
- Open Access
- 1 October 2023
- Published by AME Publishing Company in Journal of Laboratory and Precision Medicine
- Vol. 8, 27
Analytical performance of point-of-care device QuikRead go in HbA1c analysis
Background: Point-of-care (POC) analysers are crucial in acute care diagnostics. Due to easy access, they are also used in monitoring chronic diseases. However, use of POC devises in measurement of glycated haemoglobin (HbA1c) and monitoring diabetes mellitus is controversial. Methods: We compared QuikRead go analyser’s HbA1c measurement performance to cobas c513 in a clinical laboratory with leftover venous K2-ethylenediaminetetraacetic acid (K2-EDTA) samples (n=151). Results: The methods correlated well (r=0.984), but differed statistically significantly (PConclusions: This deviation in high level HbA1c should not be considered clinically acceptable. In lower HbA1c, the device showed relatively good performance. These findings demonstrate the importance of understanding analytical variation when laboratory results and various methods are used in monitoring chronic diseases.
- 1 October 2023
- Published by AME Publishing Company in Journal of Laboratory and Precision Medicine
- Vol. 8, 27
Open AccessAnalytical performance of point-of-care device QuikRead go in HbA1c analysis
Background: Point-of-care (POC) analysers are crucial in acute care diagnostics. Due to easy access, they are also used in monitoring chronic diseases. However, use of POC devises in measurement of glycated haemoglobin (HbA1c) and monitoring diabetes mellitus is controversial. Methods: We compared QuikRead go analyser’s HbA1c measurement performance to cobas c513 in a clinical laboratory with leftover venous K2-ethylenediaminetetraacetic acid (K2-EDTA) samples (n=151). Results: The methods correlated well (r=0.984), but differed statistically significantly (PConclusions: This deviation in high level HbA1c should not be considered clinically acceptable. In lower HbA1c, the device showed relatively good performance. These findings demonstrate the importance of understanding analytical variation when laboratory results and various methods are used in monitoring chronic diseases.
- Open Access
HemoScreen hematology analyzer compared to Sysmex XN for complete blood count, white blood cell differential, and detection of leukocyte abnormalities
We compared a point‐of‐care HemoScreen hematology analyzer to an automated Sysmex XN analyzer for complete blood count (CBC) and white blood cell (WBC) differential, and evaluated its capacity to detect leukocyte abnormalities. A total of 100 K2‐EDTA whole blood samples, median age 56 years (2 months to 92 years), were compared. For CBC and WBC differential we compared 74 samples with no confirmed abnormal leukocytes. For 26 samples both analyzers gave flagging regarding leukocytes and the accuracy of the flagging was compared. Abnormal leukocytes were confirmed with manual microscopy (200 cells). HemoScreen CBC and WBC differential were highly comparable to Sysmex XN for most of the essential parameters (r = 0.909–0.975). More variation was seen for basophil and monocyte counts (r = 0.452 and 0.753, respectively). Sysmex XN gave more false WBC abnormal flagging (n = 15 altogether) compared to HemoScreen. In addition, Sysmex XN, as well as HemoScreen, gave false WBC flagging for eight samples confirmed normal. The samples verified by microscopy review to truly contain leukocyte abnormalities (n = 18) were flagged abnormal with both analyzers. The specificity for analyzer flagging was 72% and 88% for Sysmex XN and HemoScreen, respectively. HemoScreen hematology analyzer is essentially comparable to Sysmex XN for CBC and WBC differential analysis. Most importantly, HemoScreen detected all the samples confirmed to include abnormal leukocytes. HemoScreen was less prone for false WBC flagging compared to Sysmex XN, thereafter requiring less microscopy review. These abilities increase its utility in small health care units. Studies with a larger number of abnormal leukocyte samples are needed to confirm HemoScreen performance.
Open AccessHemoScreen hematology analyzer compared to Sysmex XN for complete blood count, white blood cell differential, and detection of leukocyte abnormalities
We compared a point‐of‐care HemoScreen hematology analyzer to an automated Sysmex XN analyzer for complete blood count (CBC) and white blood cell (WBC) differential, and evaluated its capacity to detect leukocyte abnormalities. A total of 100 K2‐EDTA whole blood samples, median age 56 years (2 months to 92 years), were compared. For CBC and WBC differential we compared 74 samples with no confirmed abnormal leukocytes. For 26 samples both analyzers gave flagging regarding leukocytes and the accuracy of the flagging was compared. Abnormal leukocytes were confirmed with manual microscopy (200 cells). HemoScreen CBC and WBC differential were highly comparable to Sysmex XN for most of the essential parameters (r = 0.909–0.975). More variation was seen for basophil and monocyte counts (r = 0.452 and 0.753, respectively). Sysmex XN gave more false WBC abnormal flagging (n = 15 altogether) compared to HemoScreen. In addition, Sysmex XN, as well as HemoScreen, gave false WBC flagging for eight samples confirmed normal. The samples verified by microscopy review to truly contain leukocyte abnormalities (n = 18) were flagged abnormal with both analyzers. The specificity for analyzer flagging was 72% and 88% for Sysmex XN and HemoScreen, respectively. HemoScreen hematology analyzer is essentially comparable to Sysmex XN for CBC and WBC differential analysis. Most importantly, HemoScreen detected all the samples confirmed to include abnormal leukocytes. HemoScreen was less prone for false WBC flagging compared to Sysmex XN, thereafter requiring less microscopy review. These abilities increase its utility in small health care units. Studies with a larger number of abnormal leukocyte samples are needed to confirm HemoScreen performance.
- 4 February 2021
- Published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences
- Vol. 58 (5) , 329-353
Presentation and formatting of laboratory results: a narrative review on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group “postanalytical phase” (WG-POST)
In laboratory medicine, much effort has been put into analytical quality in the past decades, making this medical profession one of the most standardized with the lowest rates of error. However, even the best analytical quality cannot compensate for errors or low quality in the pre or postanalytical phase of the total testing process. Guidelines for data reporting focus solely on defined data elements, which have to be provided alongside the analytical test results. No guidelines on how to format laboratory reports exist. The habit of reporting as much diagnostic data as possible, including supplemental information, may lead to an information overload. Considering the multiple tasks physicians have to do simultaneously, unfiltered data presentation may contribute to patient risk, as important information may be overlooked, or juxtaposition errors may occur. As laboratories should aim to answer clinical questions, rather than providing sole analytical results, optimizing formatting options may help improve the effectiveness and efficiency of medical decision-making. In this narrative review, we focus on the underappreciated topic of laboratory result reporting. We present published literature, focusing on the impact of laboratory result report formatting on medical decisions as well as approaches, potential benefits, and limitations for alternative report formats. We discuss influencing variables such as, for example, the type of patient (e.g. acute versus chronic), the medical specialty of the recipient of the report, the display of reference intervals, the medium or platform on which the laboratory report is presented (printed paper, within electronic health record systems, on handheld devices, etc.), the context in which the report is viewed in, and difficulties in formatting single versus cumulative reports. Evidence on this topic, especially experimental studies, is scarce. When considering the medical impact, it is of utmost importance that laboratories focus not only on the analytical aspects but on the total testing process. The achievement of high analytical quality may be of minor value if essential results get lost in overload or scattering of information by using a non-formatted tabular design. More experimental studies to define guidelines and to standardize effective and efficient reporting are most definitely needed.
- 4 February 2021
- Published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences
- Vol. 58 (5) , 329-353
Presentation and formatting of laboratory results: a narrative review on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group “postanalytical phase” (WG-POST)
In laboratory medicine, much effort has been put into analytical quality in the past decades, making this medical profession one of the most standardized with the lowest rates of error. However, even the best analytical quality cannot compensate for errors or low quality in the pre or postanalytical phase of the total testing process. Guidelines for data reporting focus solely on defined data elements, which have to be provided alongside the analytical test results. No guidelines on how to format laboratory reports exist. The habit of reporting as much diagnostic data as possible, including supplemental information, may lead to an information overload. Considering the multiple tasks physicians have to do simultaneously, unfiltered data presentation may contribute to patient risk, as important information may be overlooked, or juxtaposition errors may occur. As laboratories should aim to answer clinical questions, rather than providing sole analytical results, optimizing formatting options may help improve the effectiveness and efficiency of medical decision-making. In this narrative review, we focus on the underappreciated topic of laboratory result reporting. We present published literature, focusing on the impact of laboratory result report formatting on medical decisions as well as approaches, potential benefits, and limitations for alternative report formats. We discuss influencing variables such as, for example, the type of patient (e.g. acute versus chronic), the medical specialty of the recipient of the report, the display of reference intervals, the medium or platform on which the laboratory report is presented (printed paper, within electronic health record systems, on handheld devices, etc.), the context in which the report is viewed in, and difficulties in formatting single versus cumulative reports. Evidence on this topic, especially experimental studies, is scarce. When considering the medical impact, it is of utmost importance that laboratories focus not only on the analytical aspects but on the total testing process. The achievement of high analytical quality may be of minor value if essential results get lost in overload or scattering of information by using a non-formatted tabular design. More experimental studies to define guidelines and to standardize effective and efficient reporting are most definitely needed.
- 20 August 2020
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 52 (2) , 168-173
Reporting Sysmex XN Absolute Neutrophil Count in Samples with Leukocyte Analyzer Flagging
Objective: To provide faster laboratory data reporting, we evaluated the accuracy of Sysmex XN (Sysmex Inc, Kobe, Japan) absolute neutrophil count (ANC) in the presence of analyzer flagging. Methods: Sysmex XN and manual microscopy ANC were compared with 80 autovalidated control specimens and with 280 study specimens with analyzer flagging regarding immature granulocytes (IG) >3% or other leukocyte abnormalities. Specimens with ambiguous neutrophil clusters were excluded. Results: A slight positive overall method bias was seen for Sysmex XN compared to manual microscopy (n = 280), 0.025 (95% confidence interval [CI], –0.023 to 0.069) × 109/L. With IG > 10% (n = 123) the bias was larger, but not clinically significant, 0.17 (95% CI, 0.060–0.25) × 109/L. No clinically significant difference was seen in neutropenic (ANC < 1.5 × 109/L) specimens (n = 91), 0.070 (95% CI, –0.013 to 0.14) × 109/L. Conclusion: These data indicate that Sysmex XN ANC can be reported in the presence of certain analyzer flagging to improve patient care.
- 20 August 2020
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 52 (2) , 168-173
Reporting Sysmex XN Absolute Neutrophil Count in Samples with Leukocyte Analyzer Flagging
Objective: To provide faster laboratory data reporting, we evaluated the accuracy of Sysmex XN (Sysmex Inc, Kobe, Japan) absolute neutrophil count (ANC) in the presence of analyzer flagging. Methods: Sysmex XN and manual microscopy ANC were compared with 80 autovalidated control specimens and with 280 study specimens with analyzer flagging regarding immature granulocytes (IG) >3% or other leukocyte abnormalities. Specimens with ambiguous neutrophil clusters were excluded. Results: A slight positive overall method bias was seen for Sysmex XN compared to manual microscopy (n = 280), 0.025 (95% confidence interval [CI], –0.023 to 0.069) × 109/L. With IG > 10% (n = 123) the bias was larger, but not clinically significant, 0.17 (95% CI, 0.060–0.25) × 109/L. No clinically significant difference was seen in neutropenic (ANC < 1.5 × 109/L) specimens (n = 91), 0.070 (95% CI, –0.013 to 0.14) × 109/L. Conclusion: These data indicate that Sysmex XN ANC can be reported in the presence of certain analyzer flagging to improve patient care.
- Open Access
- 12 May 2020
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 59 (3) , 505-512
A proposed Common Training Framework for Specialists in Laboratory Medicine under EU Directive 2013/55/EC (The Recognition of Professional Qualifications)
European Union (EU) Directive 2013/55/EC (The Recognition of Professional Qualifications) allows Member States to decide on a common set of minimum knowledge, skills and competences that are needed to pursue a given profession through a Common Training Framework. To be adopted the framework must combine the knowledge, skills and competences of at least one third of the Member States. Professionals who have gained their qualifications under a Common Training Framework will be able to have these recognised automatically within the Union. The backbone of the European Federation of Clinical Chemistry and Laboratory Medicine’s (EFLM) proposed Common Training Framework for non-medical Specialists in Laboratory Medicine is outlined here. It is based on an Equivalence of Standards in education, training, qualifications, knowledge, skills, competences and the professional conduct associated with specialist practice. In proposing the recognition of specialist practice EFLM has identified 15 EU Member States able to meet Equivalence and in whom the profession and/or its training is regulated (an additional EU Commission requirement). The framework supports and contributes to the Directive’s enabling goals for increasing professional mobility, safeguarding consumers and ensuring a more equitable distribution of skills and expertise across the Member States. It represents EFLM’s position statement and provides a template for professional societies and/or competent authorities to engage with the EU Commission.
- 12 May 2020
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 59 (3) , 505-512
Open AccessA proposed Common Training Framework for Specialists in Laboratory Medicine under EU Directive 2013/55/EC (The Recognition of Professional Qualifications)
European Union (EU) Directive 2013/55/EC (The Recognition of Professional Qualifications) allows Member States to decide on a common set of minimum knowledge, skills and competences that are needed to pursue a given profession through a Common Training Framework. To be adopted the framework must combine the knowledge, skills and competences of at least one third of the Member States. Professionals who have gained their qualifications under a Common Training Framework will be able to have these recognised automatically within the Union. The backbone of the European Federation of Clinical Chemistry and Laboratory Medicine’s (EFLM) proposed Common Training Framework for non-medical Specialists in Laboratory Medicine is outlined here. It is based on an Equivalence of Standards in education, training, qualifications, knowledge, skills, competences and the professional conduct associated with specialist practice. In proposing the recognition of specialist practice EFLM has identified 15 EU Member States able to meet Equivalence and in whom the profession and/or its training is regulated (an additional EU Commission requirement). The framework supports and contributes to the Directive’s enabling goals for increasing professional mobility, safeguarding consumers and ensuring a more equitable distribution of skills and expertise across the Member States. It represents EFLM’s position statement and provides a template for professional societies and/or competent authorities to engage with the EU Commission.